Clinical Trials Browser

Phase 2 × INDUSTRY × lurtotecan × Clear all

NCT00046787 2011-10-20

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00046800 2011-10-20

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms